Crinetics Pharmaceuticals News Releases http://ir.crinetics.com/ Crinetics Pharmaceuticals News Releases en Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-initiates-phase-1-study-crn01941 SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the Tue, 21 May 2019 07:30:00 -0400 Crinetics Pharmaceuticals News Releases 6771 Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-reports-first-quarter-2019-financial SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial Mon, 13 May 2019 16:11:00 -0400 Crinetics Pharmaceuticals News Releases 6756 Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-doses-first-patients-phase-2-clinical SAN DIEGO , March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the Tue, 19 Mar 2019 07:30:00 -0400 Crinetics Pharmaceuticals News Releases 6726 Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-appoints-gina-ford-rph-mba-vice SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the Mon, 18 Mar 2019 07:30:00 -0400 Crinetics Pharmaceuticals News Releases 6721 Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-announces-upcoming-presentations SAN DIEGO , March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced four Thu, 14 Mar 2019 16:27:00 -0400 Crinetics Pharmaceuticals News Releases 6716 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year SAN DIEGO , March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial Wed, 13 Mar 2019 16:05:00 -0400 Crinetics Pharmaceuticals News Releases 6706 Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-present-svb-leerink-global-healthcare SAN DIEGO , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Thu, 21 Feb 2019 07:30:00 -0500 Crinetics Pharmaceuticals News Releases 6666 Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-present-jp-morgan-healthcare-0 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Wed, 02 Jan 2019 16:05:00 -0500 Crinetics Pharmaceuticals News Releases 6621 Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-participate-piper-jaffray-30th-annual SAN DIEGO , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Tue, 20 Nov 2018 07:30:00 -0500 Crinetics Pharmaceuticals News Releases 6606 Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update http://ir.crinetics.com/news-releases/news-release-details/crinetics-pharmaceuticals-reports-third-quarter-2018-financial SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial Tue, 13 Nov 2018 16:05:00 -0500 Crinetics Pharmaceuticals News Releases 6591